Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 6/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.72 |
| ▸ | TTR | P02766 | 2/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.72 |
| ▸ | MYC | P01106 | 1/20 | 0.72 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.71 |
| ▸ | TUBB | P07437 | 4/20 | 0.71 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.71 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.71 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.71 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.71 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.71 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.71 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.71 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.71 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.71 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.71 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.71 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284984 | 1.00 | NQO2 (0.72) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL14027997 | 1.00 | NQO2 (0.72) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2966692 | 0.91 | ALOX5 (0.64) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2966686 | 0.91 | ALOX5 (0.64) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2976605 | 0.90 | NQO2 (0.59) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2971372 | 0.90 | NQO2 (0.59) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2971377 | 0.90 | NQO2 (0.59) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2976010 | 0.90 | ESR1 (0.64) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2976014 | 0.90 | ESR1 (0.64) | NQO2CYP1A1CYP1B1TTRABCG2 | |
| SCHEMBL2976085 | 0.90 | ESR1 (0.64) | NQO2CYP1A1CYP1B1TTRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116196427-A | Compositions and methods for immune-mediated cancer therapy | 泰克利森有限公司 | 2023-06-02 | — | — | CN | claimed |
| US-20190070186-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison, Inc. | 2019-03-07 | — | — | US | claimed |
| CN-108472366-A | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | 泰克利森有限公司 | 2018-08-31 | — | — | CN | claimed |
| EP-3365015-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison Limited (KY) | 2018-08-29 | — | — | EP | claimed |
| US-9649316-B2 | Induction of tumor hypoxia for cancer therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-05-16 | — | — | US | claimed |
| WO-2017070606-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | TECLISON LIMITED (KY) | 2017-04-27 | — | — | WO | claimed |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-03-06 | — | — | US | claimed |
| WO-2009126705-A2 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2009-10-15 | — | — | WO | claimed |
| US-20250255877-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison, Inc. | 2025-08-14 | — | — | US | disclosed |
| US-12350275-B2 | Compositions and methods for immune-mediated cancer therapy | Teclison, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-116196427-A | Compositions and methods for immune-mediated cancer therapy | 泰克利森有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230133566-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | Teclison, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11534445-B2 | Compositions and methods for immune-mediated cancer therapy | TECLISON LIMITED (KY) | 2022-12-27 | — | — | US | disclosed |
| EP-3212613-B1 | (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS | COUNCIL SCIENT IND RES (IN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2009126705-A2 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008131320-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008131320-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261982-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2008-10-23 | — | — | US | disclosed |
| US-20080261982-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2008-10-23 | — | — | US | disclosed |
| US-20080261982-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261982-A1 | STILBENE DERIVATIVES AS NEW CANCER THERAPEUTIC AGENTS | HDGF, TIE1, VEGFA | NQO2 4026/4885CYP1A1 2643/4885CYP1B1 1877/4885 |
| US-20230133566-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | CD47, HIF1AN, HIF1A | NQO2 490/4885CYP1A1 2430/4885CYP1B1 3796/4885 |
| US-11534445-B2 | Compositions and methods for immune-mediated cancer therapy | CD47, HIF1AN, HIF1A | NQO2 490/4885CYP1A1 2430/4885CYP1B1 3796/4885 |
| US-20140065139-A1 | Induction of Tumor Hypoxia for Cancer Therapy | HIF1A, HIF1AN, HYOU1 | NQO2 990/4885CYP1A1 1941/4885CYP1B1 3885/4885 |
| US-20190070186-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | CD47, HIF1AN, HIF1A | NQO2 490/4885CYP1A1 2430/4885CYP1B1 3796/4885 |
| US-20250255877-A1 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | CD47, HIF1AN, HIF1A | NQO2 490/4885CYP1A1 2430/4885CYP1B1 3796/4885 |
| US-12350275-B2 | Compositions and methods for immune-mediated cancer therapy | CD47, HIF1AN, HIF1A | NQO2 490/4885CYP1A1 2430/4885CYP1B1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.